Kornimate/medical-research-clean huggingface dataset:
cancer development in organ transplant recipients

Conditions: Heart Cancer; Kidney Cancer; Lung Cancer; Pancreas Cancer; Liver Cancer

Summary: the investigators will determine the cancer risk in organ transplant recipients compared to the general population with the help of statistical analysis. secondly the investigators will try to characterize the different cancer types.

this cohort analyses will focus on incident and recurrent cases of development of non-skin cancer over time. we will consider time to first formation of non-skin solid cancer after solid organ transplantation as well as the cumulative number of non-skin solid cancer formation over time. both aspects are equally important and will be reflected in the analytic methods of this study. theses analyses will be restricted to the most prevalent transplantation types of heart, kidney, liver, and lung.

Eligibility criteria:
inclusion criteria: we will select all patients within the stcs based on the date of the first solid organ transplantation. patients with multiple organ transplantations will be included as well. patients contribute to the study observation time until death or end of follow-up due to other reasons. exclusion criteria: we will exclude patients with non-solid organ transplantation (e.g. hematopoietic stem cell transplantation), because the detailing of information in the stcs is insufficient to allow for detailed analysis of cancer development and control of relevant confounders. we will exclude
comparison of different manual therapy approaches in patients with chronic neck pain

Conditions: Neck Pain

Summary: the aim of the study was to compare the effects of different manual therapy approaches on pain, cervical range of motion, balance, functional status and life quality in patients with chronic neck pain.

various physiotherapy and rehabilitation methods are applied in the treatment of patients with chronic neck pain. clinical practice guidelines for individuals with chronic neck pain recommend both manual therapy and exercise therapy among conservative treatments. manual therapy are methods that can be safely applied to soft tissues and joints. both manual therapy and exercise applications have been shown to have positive effects on neck pain and function. some studies in the literature have also shown that manual therapy methods have positive effects on balance. however, no study examining the effects of different manual therapy (classical massage, connective tissue massage, manual joint techniques) approaches applied to individuals with chronic neck pain on pain, cervical range of motion, balance, functional status and quality of life was found in the literature.

Eligibility criteria:
inclusion criteria: * to be between the ages of 18-65. * to participate in the study voluntarily. * having a complaint of neck pain for at least 3 months. exclusion criteria: * to have undergone cervical spine surgery * having cervical fracture and/or joint subluxation/dislocation * severe degenerative arthritis * having a neurological disease (parkinson's disease, poliomyelitis, etc.) or an -inflammatory rheumatic disease (ankylosing spondylitis, rheumatoid arthritis, etc.) * presence of malignancy * having cord compression and signs * severe radiculopathy or myelopathy * positive vertebrobasilar artery test, * pregnancy
thor study: a study of continued herceptin (trastuzumab) in combination with second line chemotherapy in patients with her2 positive metastatic breast cancer.

Conditions: Breast Cancer

Summary: this 2 arm study will compare the efficacy and safety of continuation or discontinuation of herceptin treatment in combination with 2nd line chemotherapy, in patients with her2 positive metastatic breast cancer whose condition has progressed on 1st line chemotherapy plus herceptin. patients will be randomized either to continue or discontinue herceptin treatment (2mg/kg iv infusion weekly, or 6mg/kg iv infusion every 3 weeks) while receiving 2nd line chemotherapy of the investigator's choice. the anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * female patients, \>=18 years of age; * metastatic breast cancer; * her2 overexpression (ihc 3+ and/or fish positive); * disease progression during or after previous 1st line chemotherapy plus herceptin; * scheduled to receive 2nd line chemotherapy. exclusion criteria: * incompatibility with previous herceptin therapy; * pregnancy.
clinical decision support for opioid use disorders in medical settings: usability testing in an emr

Conditions: Opioid-use Disorder

Summary: the primary objective of this pilot study is to program an opioid use disorder (oud) clinical decision support (cds) tool for use in an electronic medical record (emr) and obtain high primary care physician (pcp) usability and acceptability. the oud-cds is based on the nida-blending initiative white paper, "clinical decision support for opioid use disorders: working group report," which itself is based on national evidence-based guidelines (american society of addiction medicine (asam 2015), va (va 2015). as such, this pilot study aims to help pcps achieve accepted standards of care in oud treatment. the secondary objectives of this pilot study are to evaluate the usefulness of the tool by comparing oud case-finding, medication-assisted therapy (mat) and referral patterns pre- and post-cds deployment for pcps with and without cds access.


Eligibility criteria:
inclusion criteria: * be an md, doctor of osteopathy, nurse practitioner or physician's assistant engaged in independent primary care of adults at healthpartners or park nicollet * have at least schedule 3 dea prescribing privileges * voluntarily provide written informed consent to participate in this study exclusion criteria: * less than half-time clinical primary care responsibilities

Keywords: cds medication assisted therapy
echocardiography findings and perioperative outcomes in children

Conditions: Congenital Cardiac Defect

Summary: this study evaluates the association between perioperative echocardiographic doppler findings and clinical outcomes in pediatric patients undergoing cardiac surgery. in our center, anesthesiologists perform transthoracic or transesophageal echocardiography during perioperative period routinely in children undergoing surgery for congenital cardiac disease. echocardiographic findings include the doppler patterns of hepatic vein, portal vein, renal artery, renal vein and splenic vein before and after cardiopulmonary bypass. portal pulsatility index, renal resistive index, and respiratory variations in peak aortic blood flow velocity and diameter of inferior vena cava are measured.


Eligibility criteria:
inclusion criteria: * all pediatric patients undergoing cardiac surgery exclusion criteria: * applying extracorporeal membrane oxygenator prior to surgery * trouble applying echocardiography
cgm monitoring in t2dm patients undergoing orthopaedic replacement surgery

Conditions: Diabetes Mellitus, Type 2; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee

Summary: the purpose of this study is to analyze the efficacy and accuracy of real-time continuous glucose monitoring devices (rtcgm) in patients with type 2 diabetes undergoing inpatient elective hip or knee surgery in the pre-, peri-, and post-operative setting at stony brook university hospital (sbuh).


Eligibility criteria:
inclusion criteria: * greater than or equal to 18 years of age * scheduled for elective inpatient hip or knee replacement surgery at stony brook university hospital (sbuh) * clinically diagnosed type 2 diabetes at least 6 months prior to surgery * literate and able to provide written informed consent * negative pregnancy test by serum or urine hcg at screening \[as documented in subject's medical record) for women of childbearing potential (wcbp)\] exclusion criteria: * less than 18 years of age * not scheduled for elective inpatient hip or knee replacement surgery at sbuh * no clinical diagnosis of type 2 diabetes at least 6 months prior to surgery * not literate or unable to provide written informed consent * documented diagnosis of organ failure * documented diagnosis of chronic infection * documented diagnosis of any active malignancy * documented diagnosis of hepatic (liver) dysfunction or cirrhosis * pregnant by serum or urine hcg at screening \[as documented in subject's medical record) for women of childbearing potential (wcbp)\]

Keywords: type 2 diabetes orthopaedic hip replacement orthopaedic knee replacement continuous blood glucose monitoring
the effect of share care model in the improvement of diabetes management

Conditions: Diabetes Mellitus, Type 2

Summary: the situation of diabetes management in china is serious. to set up hierarchical medical system is necessary, though there was no mature or effective diabetes management model in the mainland. to explore a new path for hierarchical medical system, we would localize the share care model of diabetes management in taiwan. diabetic experts, diabetic educators and community doctors would use interactive information platform and self-glucose monitor with application on mobile phone to manage diabetic patients together. the model will be applied in six diabetic centers, and patients we will be managed in the new model and followed, and at the same time patients that managed in the conventional model in the real world, the differences of proportion who achieve a composite goal will be compared yearly for 5 years.


Eligibility criteria:
inclusion criteria: * type 2 diabetic patients exclusion criteria: * patients had not signed the consent form * patients with sever hart failure, hepatic failure, renal failure

Keywords: diabetes mellitus diabetic management share care
tamoxifen following combination chemotherapy in treating women with operable invasive breast cancer

Conditions: Breast Cancer

Summary: rationale: estrogen can stimulate the growth of breast cancer cells. hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. combining combination chemotherapy with hormone therapy may kill more tumor cells. purpose: randomized phase iii trial to compare the effectiveness of combination chemotherapy with or without tamoxifen in treating women with stage i or stage ii breast cancer that can be surgically removed.

objectives: i. assess the disease-free and overall survival produced by adjuvant tamoxifen given after postoperative chemotherapy with cyclophosphamide/methotrexate/fluorouracil (cmf) vs. adjuvant cmf alone in women with primary breast cancer. outline: this is a randomized study. patients are stratified by age and by participating institution. all patients undergo surgical resection with local radiation therapy, as appropriate. within 4 weeks of surgery, patients receive cyclophosphamide, methotrexate, and fluorouracil (cmf) every 3 weeks for 6 courses. radiotherapy is given within 4 weeks of completion of cmf. before beginning the last course of cmf, patients are randomized to receive either oral tamoxifen daily for 5 years or no further therapy. patients are followed every 6 months for 5 years, then yearly. hormone therapy is prohibited except as specified above and except for short-term hormone replacement therapy for severe unresponsive menopausal symptoms. projected accrual: approximately 2,000 patients will be required. data on patients entered in scotland as part of this study will be pooled with data from the eortc-10901 study.

Eligibility criteria:
disease characteristics: histologically confirmed breast cancer with palpable, unilateral, invasive disease bilateral mammography required within 1 year prior to randomization tnm stage t1-3, n0-1, m0 disease for which adjuvant chemotherapy is considered an essential part of initial therapy no prior pure in situ carcinoma in either breast no concurrent in situ carcinoma only no paget's disease of the nipple without underlying invasion no evidence of distant disease, e.g.: no ipsilateral supraclavicular node enlargement unless proven benign hormone receptor status: any status patient characteristics: age: not specified sex: women only menopausal status: pre- or postmenopausal performance status: not specified hematopoietic: not specified hepatic: not specified renal: not specified other: no serious unrelated illness no prior invasive malignancy at any other site except adequately treated nonmelanomatous skin cancer no pregnant or nursing women adequate contraception required prior concurrent therapy: no prior tamoxifen and not currently receiving tamoxifen

Keywords: stage i breast cancer stage ii breast cancer stage iiia breast cancer
immunogenicity and safety of a dtpa-hbv-ipv/hib vaccine given at 2, 3 and 4 months of age

Conditions: Acellular Pertussis; Tetanus; Diphtheria; Hepatitis B; Poliomyelitis; Haemophilus Influenzae Type b

Summary: the purpose of this study is to show that the immunogenicity of newly formulated dtpa-hbv-ipv/hib vaccine is as good as the immunogenicity of the currently licensed formulation of the vaccine. the vaccine will be administered as a primary vaccination course to healthy infants at 2, 3 and 4 months of age and its safety and reactogenicity will also be assessed.


Eligibility criteria:
inclusion criteria: * a healthy male or female between, and including, 8 and 12 weeks of age at the time of the first vaccination. * written informed consent obtained from the parents/guardians of the subject. * born after a normal gestation period of 36 to 42 weeks. exclusion criteria: * use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. * chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs from birth until first primary vaccination dose. * administration of immunoglobulins and/or any blood products since birth or planned administration during the study period. * administration/planned administration of a vaccine not foreseen by the study protocol during the period starting 30 days before the administration of the first dose and ending 30 days after the last dose, with the exception of the human rotavirus (hrv) vaccine. * concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device). * evidence of previous or intercurrent diphtheria, tetanus, pertussis, polio, hepatitis b and/or haemophilus influenza type b (hib) vaccination or disease. * hepatitis b virus (hbv) vaccination at birth. * history of seizures or progressive neurological disease.

Keywords: haemophilus influenzae type b double-blind finland randomized phase 2 gsk biologicals dtpa-hbv-ipv/hib
smartphone-based stress management intervention for employees

Conditions: Stress, Psychological

Summary: participants were able to use the application the investigators developed for four weeks. with the application, the participants were able to monitor their stress level and life style patterns. the participants were also provided personalized stress management techniques including psychoeducation and cognitive behavioral technique. in 2014, additional relaxation techniques-abdominal breathing, progressive muscular relaxation, and meditation-were incorporated. participants' mental health status and life style patterns were evaluated at baseline and at 4 weeks. pre- and post-intervention statuses were compared after adjusting for degrees of life stress factors. brief encounter psychosocial instrument (bepsi-k) score and center for epidemiologic studies depression scale (ces-d) score were used as primary outcome measures.


Eligibility criteria:
inclusion criteria: * any employee from three corporations (the korea gas corporation (kogas), the korea district heating corporation (kdhc), and the korea expressway corporation (kec)); any individual who visited the health promotion center for a health checkup at seoul national university bundang hospital exclusion criteria: * none
growth hormone deficiency and empty sella cardio-metabolic risk factors in obesity: a cross-sectional study

Conditions: Obesity

Summary: obesity is a disease not always attributable to nutritional imbalance, frequently associated with changes in key hypothalamic-pituitary (hp) axes. the regain of weight loss after hypochaloric diets has been ascribed to these hp disregulations. the aim of the study is to explore pituitary morphology and its association with pituitary function and metabolic phenotype in outpatient obese individuals evaluated in the period 2010-2013 at the department of experimental medicine of the university of rome la sapienza, with features of hp disease in a cross-sectional .


Eligibility criteria:
inclusion criteria: * adult obese exclusion criteria: * psychiatric disturbances, pregnancy, lactation, or drugs known to affect pituitary function
hyvinkää childhood obesity study (hcos), randomized controlled clinical trial for effectiveness and costs of a 1-year lifestyle intervention.

Conditions: Childhood Obesity

Summary: the aim of this study is to evaluate the effects of lifestyle intervention on the management of childhood overweight and to explore the factors that contribute to the outcome, as well as the costs for the health care system. the hypotheses of the study are that lifestyle intervention is efficient in reducing bmi-sds and thus effective in preventing overweight to progress to obesity, and it is also cost effective. the research is necessary for the development of overweight treatment, and try to find out the optimal duration and intensity for the treatment and content useful for clinical work.

methods and analyses: the aim of this study is to recruit 80 children and to randomize them either to an intervention group or a control group with standard care. intervention group receive intensive, family-based diet and physical activity counseling, deliver by a multidisciplinary team of a pediatrician, a nurse and a clinical nutritionist. control group do not receive any lifestyle intervention during the study. the inclusion criteria are weight-for-height ≥+40% or ≥+30% and increasing and age of 6-12 years. all participants fill out the study questionnaires and plasma samples are taken at baseline and at 12 months. outcome variables will be compared between intervention and control groups.

Eligibility criteria:
inclusion criteria: weight for height at least + 40 % or ≥ 30 % and it is rising exclusion criteria: clinical diagnosis of endocrine or mental diseases.
iressa expanded access program (eap)

Conditions: Carcinoma; Non-small-cell Lung; Metastases; Neoplasm

Summary: a program for patients with non small cell lung cancer who may benefit from iressa, but cannot enter another clinical trial due to them not being eligible, or for whom no trials are available.


Eligibility criteria:
inclusion criteria for inclusion in this trial, patients must fulfill all of the following criteria: * previous documented histologically or cytologically confirmed non-small cell lung cancer; * locally advanced and/or metastatic non-operable non-small cell lung cancer (stage iii or iv)patients who have received at least one course of standard systemic chemotherapy or radiation therapy or are ineligible for chemotherapy or radiotherapy or are ineligible or not a candidate for enrollment on another zd1839 trial or who, in the investigator's opinion, are not medically suitable for chemotherapy. * age 18 years or older; * written informed consent to participate in the trial. exclusion criteria any of the following will exclude a patient from entering the trial: * receiving concurrent radiotherapy, chemotherapy, or other systemic anti-cancer medication or any other investigational agent. \* non-cytotoxic or hormonal therapies for the adjuvant treatment of cancer or for previously treated cancers may be allowed per astrazeneca permission; * patients eligible for or previously enrolled on a zd1839 blinded clinical trial protocol. patients eligible for or previously enrolled on an open-label or unblinded zd1839 clinical trial may be considered for acceptance into the expanded access program with astrazeneca permission; * having other active malignancies; * incomplete healing from previous oncologic or other major surgery; * evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial; * pregnancy or breast feeding (women of child-bearing potential).

Keywords: locally advanced and/or metastatic non-operable non-small cell lung cancer (stage iii or iv) patients who have failed standard therapy.
model-based dose versus empirical dose of piperacillin/tazobactam in preterm neonates with late-onset sepsis.

Conditions: Late-Onset Neonatal Sepsis

Summary: this study aims to compare the clinical outcomes, safety and pd target attainment of the model-based dose and empirical dose of piperacillin/tazobactam in the treatment of los in premature neonates, so as to optimize the piperacillin/tazobactam dose regimen.


Eligibility criteria:
inclusion criteria: * preterm neonates: gestational age \<34 weeks; * postnatal age \> 72h; * postmenstrual age \<36 weeks; * newly diagnosed as late-onset sepsis; * parental written consent. exclusion criteria: * patient with bacterial meningitis, osteomyelitis, septic arthritis or necrotizing enterocolitis requiring surgery. * high suspicion of/confirmed fungal infection. * severe congenital malformations and/or severe organ failure. * administration of any systemic antibiotic regimen 24 h before screening. * administration of other systemic trial drug therapy. * other factors that the researcher considers unsuitable for inclusion. * post-randomization exclusion: ①patients with a positive baseline blood culture and the pathogen resistant to pip/tazo. ②patients with bacterial meningitis, fungal infection, osteomyelitis, septic arthritis or necrotizing enterocolitis requiring surgery after randomization.

Keywords: late-onset sepsis piperacillin/tazobactam model-based dose empirical dose